Pacira | PCRX - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
Assertio Holdings USD 16.73M 1.66M 2024-09
Astellas Pharma JPY 221.78B 14.94B 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Cara Therapeutics USD 2.19M 2.45M 2025-09
Coherus Biosciences USD 15M 6.26M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
J&J USD 6.75B 831M 2025-12
Ligand Pharmaceuticals USD 28.45M 8.27M 2025-09
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Novo Nordisk DKK 17.44B 1.41B 2025-12
Omeros USD 11.32M 2.48M 2024-09
Pacira USD 91.87M 70K 2025-12
Perrigo USD 255.9M 10.2M 2025-12
Pfizer USD 4.08B 894M 2025-12
Supernus Pharmaceuticals USD 122.39M 57.29M 2025-12
Teva Pharmaceutical Industries USD 1.12B 147M 2025-12
Xeris Pharmaceuticals USD 42.64M 3.82M 2025-12
Xoma USD 11M 2.54M 2024-06
Zoetis USD 619M 40M 2025-12